Shearman & Sterling advised JW (Cayman) Therapeutics Co. Ltd., a China-based cancer cell therapy developer, in connection with its primary listing on the Main Board of The Stock Exchange of Hong Kong Limited and global offering with a size of approximately HK$2.325 billion ($300 million).
JW (Cayman) Therapeutics Co. Ltd is a global leading clinical stage cell therapy platform company founded by Juno Therapeutics and WuXi AppTec. Its vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. Since its establishment in 2016, the company has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors.
The Shearman & Sterling team was led by partners Kyungwon (Won) Lee and Max Hua; associates Leo Wong, Carmen Yuen and Julie Qi; and legal assistants Jennifer Hou (all Hong Kong-Capital Markets) and Cathy Qian (Shanghai-Capital Markets).
NOTES TO EDITORS:
About Shearman & Sterling:
With more than 850 lawyers in 24 offices, Shearman & Sterling is a global law firm that partners with corporations, major financial institutions, emerging growth companies, governments and state-owned enterprises to provide the legal and industry insight needed to navigate the challenges of today and achieve their ambitions of tomorrow. Our lawyers come from some 80 countries and speak more than 60 languages.
Samily Kwok | Asia Media
T: +852 2978 8020